Janus Henderson Group PLC bought a new stake in shares of Qiagen NV (NASDAQ:QGEN) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 21,500 shares of the company’s stock, valued at approximately $677,000.
Several other hedge funds and other institutional investors have also made changes to their positions in QGEN. Jane Street Group LLC grew its holdings in Qiagen by 25.1% during the 3rd quarter. Jane Street Group LLC now owns 144,844 shares of the company’s stock valued at $4,563,000 after purchasing an additional 29,064 shares during the last quarter. Vident Investment Advisory LLC grew its holdings in Qiagen by 70.1% during the 3rd quarter. Vident Investment Advisory LLC now owns 385,068 shares of the company’s stock valued at $12,130,000 after purchasing an additional 158,694 shares during the last quarter. Atlanta Capital Management Co. L L C grew its holdings in Qiagen by 210.1% during the 3rd quarter. Atlanta Capital Management Co. L L C now owns 1,314,274 shares of the company’s stock valued at $41,400,000 after purchasing an additional 890,454 shares during the last quarter. Myriad Asset Management Ltd. bought a new position in Qiagen during the 3rd quarter valued at about $4,747,000. Finally, OxFORD Asset Management LLP grew its holdings in Qiagen by 6.7% during the 3rd quarter. OxFORD Asset Management LLP now owns 81,216 shares of the company’s stock valued at $2,558,000 after purchasing an additional 5,116 shares during the last quarter. Hedge funds and other institutional investors own 62.24% of the company’s stock.
Qiagen NV (QGEN) opened at $30.93 on Tuesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.33 and a quick ratio of 4.78. The company has a market cap of $7,059.28, a PE ratio of 79.31, a price-to-earnings-growth ratio of 1.89 and a beta of 1.10. Qiagen NV has a one year low of $27.51 and a one year high of $36.34.
Several brokerages recently commented on QGEN. Zacks Investment Research upgraded shares of Qiagen from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a report on Tuesday, October 10th. Cowen reiterated a “hold” rating and set a $33.00 price target on shares of Qiagen in a report on Friday, November 3rd. Commerzbank reiterated a “buy” rating on shares of Qiagen in a report on Tuesday, November 7th. BidaskClub upgraded shares of Qiagen from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Finally, DZ Bank reiterated a “neutral” rating on shares of Qiagen in a report on Tuesday, December 19th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $34.19.
ILLEGAL ACTIVITY NOTICE: “Janus Henderson Group PLC Buys Shares of 21,500 Qiagen NV (QGEN)” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2018/01/02/janus-henderson-group-plc-buys-shares-of-21500-qiagen-nv-qgen.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.